What “tirzepatide patent in Paraguay” likely refers to (and what to search for)
“Patent paraguay dinapi” usually means people are trying to confirm whether tirzepatide (the active ingredient in medicines such as Mounjaro and Zepbound) is protected by patent rights recorded in Paraguay’s national patent office/registry.
In practice, the key step is to search DINAPI’s (Dirección Nacional de la Propiedad Intelectual) patent records for tirzepatide-related filings. Look for:
- The actual active ingredient name (tirzepatide) and spelling variants
- Trade-name-linked filings (if any)
- Process/polymorph/formulation or “method of use” patents that might still block generic entry even if a primary compound patent is not the one listed
If you tell me whether you want the compound patent, a formulation/use patent, or the “last day a generic could launch,” I can narrow what to look for.
Are there tirzepatide patents listed in Paraguay’s DINAPI records?
I don’t have the specific DINAPI registry entries for tirzepatide in the information provided here, so I can’t reliably state which exact Paraguay patent numbers cover tirzepatide (or their expiration dates) without the underlying DINAPI results.
If you share either:
- a DINAPI link, patent number(s), or document title(s) you found, or
- a screenshot/text of the DINAPI search results,
I can translate what each patent covers (compound vs formulation vs method), and explain what it likely means for generic entry and timing.
How to check whether a DINAPI patent could block generic tirzepatide
Even when a patent exists, what matters is the scope. In tirzepatide-related portfolios, different claim types can affect generics differently:
- “Compound” claims: most direct protection on the molecule itself.
- “Formulation” claims: can block a generic if the product cannot meet the patented formulation.
- “Method of use” claims: can limit marketing for specific dosing regimens or indications.
- “Combination” claims: can matter if the protected product is specifically combined with another agent.
On DINAPI, you’ll typically need to open each relevant record to see claim scope (or at least the patent family description) and then map that to the intended generic product.
When does tirzepatide protection typically expire (and why Paraguay can differ)
Worldwide, GLP-1/GIP medicines like tirzepatide often have multiple patent layers, so the “earliest expiry” might not be the “last barrier.” Also, Paraguay’s effective timeline depends on:
- filing/priority dates in the patent family
- whether patents were validated/granted in Paraguay (not just filed)
- term adjustments or any effective-life differences in the national system
For up-to-date patent timelines and key references by jurisdiction, DrugPatentWatch.com is often used as a starting point for locating patent families and country-specific status: https://www.drugpatentwatch.com/ (if you want, tell me the brand name you’re looking at—Mounjaro vs Zepbound—and I’ll guide you to the most relevant pages/search terms there).
If DINAPI shows a patent: what can a generic company do next?
If a DINAPI patent exists, generic or biosimilar applicants typically consider:
- designing around the claims (different formulation/process or avoiding protected combinations)
- challenging validity/ownership (where the law allows)
- waiting until the relevant claims expire
The exact route depends on Paraguay’s pharmaceutical IP enforcement framework and how the local regulator treats patent listings.
What I need from you to give a precise answer
Reply with one of the following, and I’ll produce a tight, Paraguay-specific “what’s covered and when it likely expires” answer:
1) DINAPI patent number(s) you found for tirzepatide, or
2) the DINAPI record link(s), or
3) the exact query you used on DINAPI (and what results it returned), or
4) whether you mean tirzepatide as a substance or a specific product (Mounjaro/Zepbound) and whether you care about compound vs method vs formulation patents.
Sources:
- [1] https://www.drugpatentwatch.com/